A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.
Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.
Wingerchuk
D M
DM
Department of Neurology Mayo Clinic, Scottsdale, AZ 85259, USA. wingerchuk.dean@mayo.edu
Benarroch
E E
EE
O'Brien
P C
PC
Keegan
B M
BM
Lucchinetti
C F
CF
Noseworthy
J H
JH
Weinshenker
B G
BG
Rodriguez
M
M
D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D018592:Cross-Over Studies; D018450:Disease Progression; D004311:Double-Blind Method; D005221:Fatigue / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin